CRISPR Therapeutics has developed SyNTase editing, a proprietary, next-generation, site-specific gene correction platform.

Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct ...

JCR will present non-clinical data from its novel JUST-AAV gene therapy platform technology in an oral session at the ESGCT ...

A team led by scientists at Harvard Medical School, Massachusetts General Hospital, and the Broad Institute of MIT and ...

The gene therapy company uniQure has announced top-level data from its trial of AMT-130, a new gene therapy designed to treat ...

UCLA researchers have made strides in developing a stem cell gene therapy for alpha thalassemia major, a severe, inherited ...

EXTON, PA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- As the first wave of gene therapies for transfusion-dependent β-thalassemia (TDT) continues to roll out in the U.S., a new conversation is emerging within ...

At the European Cell & Gene Therapy Summit 2025, funding challenges and innovation drove discussions on the sector’s future.

After three patients died, the maker of an investigational gene therapy stopped shipments of the drug after it refused to ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...